July 19, 2011 | by Lonza Group Ltd
|
Reading time: 2 minutes
July 19, 2011, Lonza announced today an exclusive contract for the production of Immune Pharmaceutical’s human immunoglobulin monoclonal antibody, Bertilimumab, under investigation for the potential treatment of several inflammatory disorders. Under the agreement, Lonza will produce phase 2 clinical trial material at its mammalian development and manufacturing facility.
We are excited about this opportunity to support IMMUNE Pharmaceutical’s growing pipeline”, said Dr. Stephan Kutzer, COO Lonza Custom Manufacturing. “This partnership is a direct reflection of our commitment to emerging pharmaceutical companies as they advance through clinical phase milestones.”
Bertilimumab has great potential for the treatment of eosinophilic inflammatory bowel diseases (IBD) –Crohn’s Disease and Ulcerative Colitis- and eosinophilic gastro- intestinal diseases (EGID). Bertilimumab is the first monoclonal antibody to specifically neutralize human eotaxin-1, a chemokine associated with inflammatory disease activity.
Dr. Daniel Teper, CEO of IMMUNE said, “Lonza understands the needs of emerging companies, providing assistance and flexibility, while maintaining the highest standards essential for regulatory compliance and successful partnering“. IMMUNE strengthened its internal bio-manufacturing expertise by appointing to its Board of Directors, Dr David Naveh, formerly the Chief Technical Officer of Bayer Biologics Worldwide.
Contact
Lonza Group Ltd Head of Corporate Communications Dominik Werner Tel. 041 61 316 87 98 Fax 041 61 316 97 98 E-mail: dominik.werner@lonza.com
Editor's note: Image rights belong to the respective publisher.
Conclusion of this article: « Lonza signs manufacturing deal with Immune Pharmaceuticals for Bertilimumab (iCo-008) »
Source: Lonza Group Ltd, Press release